Floatz logo

DARATUMUMAB

Deletion 17P Syndrome

Fondazione EMN Italy Onlusmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Deletion 17P Syndrome cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Fondazione EMN Italy Onlus
Phase 2BB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Evomela
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
Cyclophosphamide
City of Hope Medical Center
Phase 2B
TACROLIMUS
City of Hope Medical Center
Phase 2B

View all 18 →

Same molecule, other indications

DARATUMUMAB is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
smoldering plasma cell myelomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →